On May 4, 2018 Delcath Systems, Inc. (OTCQB:DCTHD), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, reported that Jennifer K. Simpson, Ph.D., MSN, CRNP, President and Chief Executive Officer of Delcath, will present at the RHK Capital 2018 Disruptive Growth and Healthcare Conference being held May 8-9, 2018 at Reed Smith, LLP in New York. Dr. Simpson’s presentation details are as follows (Press release, Delcath Systems, MAY 4, 2018, View Source;p=RssLanding&cat=news&id=2347110 [SID1234526133]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Panel Presentation:

Session: Disruptive Injectables & Oncology
Date and Time: Tuesday, May 8 at 1:45-2:45 p.m. EST
Location: Track 2 – Room C/D
Corporate Presentation:

Date and Time: Tuesday, May 8 at 3:25-3:45 p.m. EST
Location: Room A/B